REZUROCK (belumosudil mesylate)
IMMUNOMODULATOR - RHO KINASE INHIBITOR · CHRONIC GRAFT-VERSUS-HOST DISEASE
KADMON/SANOFI-A
Drug class
Immunomodulator - Rho Kinase Inhibitor
The phrase "Immunomodulator - Rho Kinase Inhibitor" is a formulary and compendial classification rather than a formal regulatory pharmacologic class. Read more about Immunomodulator - Rho Kinase Inhibitor
1 drugs in this class 1 manufacturers
Drugs in Immunomodulator - Rho Kinase Inhibitor
Filter & compare in the drug finder →
Opens the drug finder with Immunomodulator - Rho Kinase Inhibitor preselected. Add indication or manufacturer filters there.
The phrase "Immunomodulator - Rho Kinase Inhibitor" is a formulary and compendial classification rather than a formal regulatory pharmacologic class.
It refers to systemic agents that target Rho-associated coiled-coil containing protein kinase (primarily ROCK2) to balance immune responses and suppress fibrotic pathways.
By downregulating proinflammatory Th17 cells, enhancing regulatory T cells, and blunting myofibroblast activation, these therapies resolve aberrant inflammation and tissue remodeling.
In clinical therapeutics, the representative oral agent in this group is indicated primarily for chronic graft-versus-host disease following systemic therapy failure.
-
kaiserpermanente.org
The phrase "Immunomodulator - Rho Kinase Inhibitor" is a formulary and compendial classification rather than a formal regulatory pharmacologic class
-
fda.gov
The phrase "Immunomodulator - Rho Kinase Inhibitor" is a formulary and compendial classification rather than a formal regulatory pharmacologic class
-
fda.gov
It refers to systemic agents that target Rho-associated coiled-coil containing protein kinase (primarily ROCK2) to balance immune responses and suppress fibrotic pathways By downregulating proinflammatory Th17 cells, enhancing regulatory T cells, and blunting myofibroblast activation, these therapies resolve aberrant inflammation and tissue remodeling
-
cancer.gov
It refers to systemic agents that target Rho-associated coiled-coil containing protein kinase (primarily ROCK2) to balance immune responses and suppress fibrotic pathways By downregulating proinflammatory Th17 cells, enhancing regulatory T cells, and blunting myofibroblast activation, these therapies resolve aberrant inflammation and tissue remodeling
-
cancer.gov
In clinical therapeutics, the representative oral agent in this group is indicated primarily for chronic graft-versus-host disease following systemic therapy failure
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.